NYSTATIN- nystatin suspension
Pharmaceutical Associates, Inc.

Nystatin Oral Suspension USP

Rx only

DESCRIPTION

Nystatin is an antimycotic polyene antibiotic obtained from *Streptomyces noursei*. Structural formula:



Nystatin Oral Suspension, for oral administration, contains 100,000 USP Nystatin Units per mL.

Inactive ingredients: alcohol (≤ 1% v/v), artificial wild cherry flavor, banana flavor, D&C Yellow #10, FD&C Red #40, glycerin, USP, magnesium aluminum silicate, methylparaben, NF, potassium phosphate dibasic, USP, propylene glycol, USP, propylparaben, NF, purified water, USP, and sucrose 33.5%. May also contain citric acid, USP for pH adjustment.

CLINICAL PHARMACOLOGY

Pharmacokinetics

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

Nystatin is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast-like fungi. *Candida albicans* demonstrates no significant resistance to nystatin *in vitro* on repeated subculture in increasing levels of nystatin; other *Candida* species become quite resistant. Generally, resistance does not develop *in vivo*. Nystatin acts by binding to sterols in the cell membrane of susceptible *Candida* species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

General

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

Teratogenic Effects Category C

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

Pediatric Use

See **DOSAGE AND ADMINISTRATION.**

ADVERSE REACTIONS

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See **PRECAUTIONS: General**).

Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

OVERDOSAGE

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see **CLINICAL PHARMACOLOGY, Pharmacokinetics**).

DOSAGE AND ADMINISTRATION

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use a calibrated dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times

daily is effective.

CHILDREN AND ADULTS: 4-6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.

HOW SUPPLIED

Nystatin Oral Suspension USP, 100,000 USP Nystatin Units per mL, is available as a fruit flavored, light creamy yellow, ready-to-use suspension in unit dose cups of 5 mL, 10 cups per tray. NDC 0121-4785-05.

Storage

Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Protect from freezing.

Manufactured by:
Morton Grove Pharmaceuticals, Inc.
Morton Grove, IL 60053

Packaged by:
Pharmaceutical Associates, Inc.,
Greenville, SC 29605

R06/09

PRINCIPAL DISPLAY PANEL - 5 mL Lid

Delivers **5 mL**
NDC 0121-4785-05

NYSTATIN
ORAL SUSPENSION USP

500,000 units / 5 mL

Alcohol ≤ 1% v/v **SHAKE WELL**

FOR INSTITUTIONAL USE ONLY
Rx ONLY

Manufactured by: Morton Grove Pharmaceuticals, Inc.
Morton Grove, IL 60053

Packaged by: Pharmaceutical Associates, Inc.,
Greenville, SC 29605

SEE INSERT



NYSTATIN

nystatin suspension

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:0121-4785
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**

Nystatin (UNII: BDF1O1C72E) (Nystatin - UNII:BDF1O1C72E)	Nystatin	100000 [USP'U] in 1 mL

Inactive Ingredients	
Ingredient Name	**Strength**
ALCOHOL (UNII: 3K9958V90M)	
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)	
GLYCERIN (UNII: PDC6A3C0OX)	
MAGNESIUM ALUMINUM SILICATE (UNII: 6M3P64V0NC)	
METHYLPARABEN (UNII: A2I8C7HI9T)	
POTASSIUM PHOSPHATE, DIBASIC (UNII: CI71S98N1Z)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	
PROPYLPARABEN (UNII: Z8IX2SC1OH)	
WATER (UNII: 059QF0KO0R)	
SUCROSE (UNII: C151H8M554)	
CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)	

Product Characteristics			
Color	YELLOW (LIGHT/CREAM)	**Score**	
Shape		**Size**	
Flavor	CHERRY, BANANA (FRUIT)	**Imprint Code**	
Contains			

Packaging				
#	**Item Code**	**Package Description**	**Marketing Start Date**	**Marketing End Date**
1	NDC:0121-4785-05	4 in 1 CASE		
1		10 in 1 TRAY		
1		5 mL in 1 CUP, UNIT-DOSE		
2	NDC:0121-4785-35	10 in 1 CASE		
2		10 in 1 TRAY		
2		5 mL in 1 CUP, UNIT-DOSE		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA062512	06/01/2009	

Labeler - Pharmaceutical Associates, Inc. (044940096)

Establishment

Name	Address	ID/FEI	Business Operations
Pharmaceutical Associates, Inc.		097630693	REPACK(0121-4785)

Establishment

Name	Address	ID/FEI	Business Operations
Morton Grove Pharmaceuticals, Inc.		801897505	MANUFACTURE(0121-4785)

Revised: 12/2013 Pharmaceutical Associates, Inc.